NCT04421560 2026-02-20
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
Clinical Trials
17 trialsNCT06536049 2026-02-19
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07082868 2026-02-17
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06357676 2026-01-30
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
OHSU Knight Cancer Institute
Phase 1/2 Recruiting
NCT05106296 2026-01-09
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Augusta University
Phase 1 Recruiting
NCT06271616 2025-12-26
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Mayo Clinic
Phase 2 Recruiting
NCT07052695 2025-12-15
Mosunetuzumab for CLL MRD Clearance
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06958705 2025-11-25
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT03128879 2025-11-21
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06482684 2024-07-01
CARMAN
Ludwig-Maximilians - University of Munich
Phase 2 Recruiting
NCT04061512 2024-05-10
RAINBOW
University College, London
Phase 2/3 Recruiting
NCT05694312 2023-12-01
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Recruiting
NCT04758975 2023-10-04
VALUABLE
IRCCS San Raffaele
Phase 2 Recruiting
NCT04908228 2023-10-03
FIGHT
IRCCS San Raffaele
Phase 2 Recruiting
NCT04771507 2021-02-25
IbruOnOff
Karolinska University Hospital
Phase 1/2 Recruiting
NCT03980002 2019-06-10
BDHCLL001
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT02858258 2017-12-19
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
European Mantle Cell Lymphoma Network
Phase 3 Recruiting